The combinatorial treatment using a BRAF followed by a MEK inhibitor in melanoma patients, though lacking a significant difference in progression free or overall survival compared to monotherapy, came with a partial or, in some cases, even complete response of the patients (NCT01584648, Table 2). Here, BRAF is linked to melanoma.